 Robert Ryu
Concepts (459)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vena Cava Filters | 19 | 2018 | 50 | 5.800 |
Why?
| | Liver Neoplasms | 60 | 2014 | 527 | 4.210 |
Why?
| | Embolization, Therapeutic | 41 | 2014 | 192 | 3.490 |
Why?
| | Carcinoma, Hepatocellular | 41 | 2014 | 227 | 3.230 |
Why?
| | Yttrium Radioisotopes | 39 | 2014 | 57 | 3.040 |
Why?
| | Device Removal | 13 | 2018 | 127 | 2.960 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 7 | 2019 | 39 | 2.040 |
Why?
| | Radiography, Interventional | 17 | 2016 | 113 | 1.870 |
Why?
| | Radiology, Interventional | 5 | 2019 | 28 | 1.860 |
Why?
| | Pulmonary Embolism | 9 | 2018 | 183 | 1.830 |
Why?
| | Chemoembolization, Therapeutic | 21 | 2014 | 51 | 1.780 |
Why?
| | Hypertension, Portal | 5 | 2016 | 67 | 1.480 |
Why?
| | Radiopharmaceuticals | 18 | 2014 | 194 | 1.260 |
Why?
| | Lumbar Vertebrae | 3 | 2020 | 215 | 1.230 |
Why?
| | Uterine Neoplasms | 9 | 2010 | 76 | 1.200 |
Why?
| | Educational Measurement | 2 | 2020 | 289 | 1.190 |
Why?
| | Portal Vein | 4 | 2016 | 90 | 1.040 |
Why?
| | Microspheres | 29 | 2013 | 130 | 0.990 |
Why?
| | Vena Cava, Inferior | 5 | 2018 | 55 | 0.940 |
Why?
| | Venous Thrombosis | 5 | 2017 | 147 | 0.940 |
Why?
| | Treatment Outcome | 66 | 2019 | 9346 | 0.940 |
Why?
| | Prosthesis Design | 6 | 2017 | 285 | 0.940 |
Why?
| | Practice Patterns, Physicians' | 8 | 2020 | 1200 | 0.940 |
Why?
| | Magnetic Resonance Imaging, Interventional | 8 | 2014 | 20 | 0.920 |
Why?
| | Specialty Boards | 2 | 2020 | 39 | 0.900 |
Why?
| | Total Disc Replacement | 2 | 2020 | 15 | 0.880 |
Why?
| | Intervertebral Disc | 3 | 2020 | 37 | 0.860 |
Why?
| | Uterus | 6 | 2007 | 197 | 0.810 |
Why?
| | Venous Insufficiency | 3 | 2007 | 11 | 0.810 |
Why?
| | Leiomyoma | 7 | 2007 | 45 | 0.800 |
Why?
| | Saphenous Vein | 3 | 2007 | 32 | 0.790 |
Why?
| | Thromboembolism | 3 | 2017 | 99 | 0.780 |
Why?
| | Postoperative Complications | 5 | 2020 | 2235 | 0.750 |
Why?
| | Laser Therapy | 3 | 2007 | 104 | 0.730 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2020 | 28 | 0.720 |
Why?
| | Prosthesis Implantation | 3 | 2017 | 141 | 0.710 |
Why?
| | Intervertebral Disc Displacement | 1 | 2020 | 39 | 0.700 |
Why?
| | Venous Thromboembolism | 4 | 2017 | 234 | 0.670 |
Why?
| | Magnetic Resonance Angiography | 10 | 2014 | 210 | 0.670 |
Why?
| | Graft Occlusion, Vascular | 2 | 2018 | 35 | 0.670 |
Why?
| | Middle Aged | 78 | 2019 | 27627 | 0.660 |
Why?
| | Endovascular Procedures | 4 | 2020 | 275 | 0.660 |
Why?
| | Low Back Pain | 1 | 2020 | 100 | 0.640 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2018 | 16 | 0.630 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 3 | 2019 | 176 | 0.630 |
Why?
| | Ultrasonography, Interventional | 3 | 2016 | 155 | 0.610 |
Why?
| | Humans | 133 | 2020 | 119032 | 0.610 |
Why?
| | Spine | 1 | 2019 | 144 | 0.610 |
Why?
| | Magnetic Resonance Imaging | 25 | 2015 | 3175 | 0.610 |
Why?
| | Ascites | 2 | 2016 | 37 | 0.590 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2017 | 64 | 0.590 |
Why?
| | Aged | 60 | 2018 | 19661 | 0.590 |
Why?
| | Stents | 8 | 2015 | 457 | 0.590 |
Why?
| | Spinal Fusion | 2 | 2019 | 225 | 0.580 |
Why?
| | Orthopedic Procedures | 1 | 2019 | 225 | 0.560 |
Why?
| | Tomography, X-Ray Computed | 23 | 2018 | 2436 | 0.560 |
Why?
| | Time Factors | 23 | 2020 | 6414 | 0.560 |
Why?
| | Esophageal and Gastric Varices | 1 | 2016 | 40 | 0.540 |
Why?
| | Aged, 80 and over | 32 | 2018 | 6562 | 0.540 |
Why?
| | Female | 93 | 2019 | 61588 | 0.540 |
Why?
| | Digestive System Neoplasms | 1 | 2015 | 7 | 0.540 |
Why?
| | Brachytherapy | 8 | 2008 | 103 | 0.540 |
Why?
| | Intervertebral Disc Degeneration | 1 | 2016 | 29 | 0.540 |
Why?
| | Social Media | 1 | 2017 | 133 | 0.510 |
Why?
| | Diagnostic Imaging | 3 | 2017 | 294 | 0.510 |
Why?
| | Cholestasis | 2 | 2015 | 228 | 0.500 |
Why?
| | Male | 81 | 2020 | 57818 | 0.500 |
Why?
| | Adult | 54 | 2020 | 31525 | 0.490 |
Why?
| | Renal Dialysis | 1 | 2018 | 378 | 0.480 |
Why?
| | Retrospective Studies | 32 | 2019 | 12990 | 0.480 |
Why?
| | Clinical Competence | 2 | 2019 | 951 | 0.460 |
Why?
| | Imaging, Three-Dimensional | 5 | 2011 | 499 | 0.410 |
Why?
| | Angiography | 11 | 2011 | 185 | 0.400 |
Why?
| | Liver Cirrhosis | 6 | 2019 | 245 | 0.400 |
Why?
| | Cholangiocarcinoma | 4 | 2013 | 38 | 0.390 |
Why?
| | Risk Factors | 17 | 2017 | 9003 | 0.380 |
Why?
| | Uterine Artery Embolization | 1 | 2010 | 6 | 0.370 |
Why?
| | Drainage | 3 | 2019 | 158 | 0.370 |
Why?
| | Perfusion Imaging | 1 | 2010 | 44 | 0.370 |
Why?
| | Vascular System Injuries | 3 | 2016 | 70 | 0.360 |
Why?
| | Chicago | 6 | 2017 | 45 | 0.360 |
Why?
| | Adenoma, Islet Cell | 1 | 2009 | 10 | 0.360 |
Why?
| | Liver Abscess | 1 | 2009 | 3 | 0.360 |
Why?
| | Thyroid Gland | 1 | 2009 | 84 | 0.350 |
Why?
| | Observer Variation | 3 | 2010 | 309 | 0.350 |
Why?
| | Polyvinyl Alcohol | 3 | 2005 | 14 | 0.350 |
Why?
| | Contrast Media | 12 | 2016 | 373 | 0.330 |
Why?
| | Hepatic Veins | 1 | 2008 | 31 | 0.330 |
Why?
| | Phlebography | 6 | 2015 | 40 | 0.330 |
Why?
| | Gelatin | 2 | 2005 | 36 | 0.330 |
Why?
| | Predictive Value of Tests | 10 | 2015 | 1868 | 0.330 |
Why?
| | Pancreatic Neoplasms | 3 | 2010 | 734 | 0.320 |
Why?
| | Portography | 4 | 2016 | 13 | 0.320 |
Why?
| | Databases, Factual | 7 | 2020 | 1231 | 0.320 |
Why?
| | Neovascularization, Pathologic | 5 | 2009 | 287 | 0.310 |
Why?
| | Referral and Consultation | 1 | 2012 | 648 | 0.310 |
Why?
| | Lymphangioma, Cystic | 1 | 2007 | 4 | 0.310 |
Why?
| | Radiation Dosage | 5 | 2016 | 147 | 0.310 |
Why?
| | Bile Duct Neoplasms | 4 | 2013 | 55 | 0.300 |
Why?
| | Liver Transplantation | 5 | 2015 | 847 | 0.300 |
Why?
| | Catheterization | 7 | 2013 | 164 | 0.300 |
Why?
| | Prosthesis Failure | 3 | 2017 | 120 | 0.300 |
Why?
| | Angioplasty | 1 | 2007 | 39 | 0.300 |
Why?
| | Aortography | 1 | 2007 | 52 | 0.300 |
Why?
| | Antineoplastic Agents | 6 | 2014 | 1974 | 0.300 |
Why?
| | Hepatic Artery | 5 | 2010 | 55 | 0.290 |
Why?
| | Rabbits | 11 | 2013 | 780 | 0.290 |
Why?
| | United States | 10 | 2020 | 12557 | 0.280 |
Why?
| | Thyroid Neoplasms | 1 | 2009 | 278 | 0.280 |
Why?
| | Linear Models | 4 | 2017 | 827 | 0.280 |
Why?
| | Neoplasms | 4 | 2017 | 2179 | 0.280 |
Why?
| | Thrombosis | 3 | 1998 | 309 | 0.280 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2007 | 118 | 0.280 |
Why?
| | Acrylic Resins | 1 | 2005 | 39 | 0.270 |
Why?
| | Blood Vessel Prosthesis Implantation | 2 | 2007 | 181 | 0.260 |
Why?
| | Radiation Injuries | 5 | 2010 | 131 | 0.260 |
Why?
| | Radiology | 1 | 2008 | 199 | 0.260 |
Why?
| | Internship and Residency | 2 | 2019 | 1006 | 0.250 |
Why?
| | Blister | 1 | 2004 | 39 | 0.250 |
Why?
| | Ovary | 2 | 2003 | 205 | 0.250 |
Why?
| | Liver Neoplasms, Experimental | 3 | 2008 | 25 | 0.240 |
Why?
| | Survival Rate | 12 | 2018 | 1720 | 0.240 |
Why?
| | Arteries | 7 | 2013 | 250 | 0.240 |
Why?
| | Medicare | 2 | 2020 | 665 | 0.240 |
Why?
| | Multivariate Analysis | 7 | 2017 | 1474 | 0.240 |
Why?
| | Jugular Veins | 3 | 1997 | 47 | 0.220 |
Why?
| | Logistic Models | 6 | 2019 | 1901 | 0.220 |
Why?
| | Neoplasm Staging | 8 | 2014 | 1223 | 0.220 |
Why?
| | Fluoroscopy | 2 | 2016 | 146 | 0.210 |
Why?
| | Clinical Trials as Topic | 3 | 2013 | 968 | 0.210 |
Why?
| | Disease Progression | 14 | 2014 | 2490 | 0.210 |
Why?
| | Education, Medical, Continuing | 2 | 2017 | 125 | 0.210 |
Why?
| | Neoplasms, Experimental | 2 | 2013 | 158 | 0.210 |
Why?
| | Kaplan-Meier Estimate | 9 | 2015 | 842 | 0.210 |
Why?
| | Constriction, Pathologic | 3 | 2019 | 204 | 0.200 |
Why?
| | Chi-Square Distribution | 6 | 2014 | 525 | 0.200 |
Why?
| | Liver | 7 | 2013 | 1816 | 0.200 |
Why?
| | Reoperation | 4 | 2019 | 557 | 0.200 |
Why?
| | Disease Models, Animal | 6 | 2016 | 3730 | 0.200 |
Why?
| | Vascular Patency | 3 | 2018 | 98 | 0.200 |
Why?
| | Medical Oncology | 2 | 2013 | 229 | 0.200 |
Why?
| | Angiography, Digital Subtraction | 6 | 2014 | 46 | 0.200 |
Why?
| | Catheter Ablation | 1 | 2004 | 286 | 0.200 |
Why?
| | alpha-Fetoproteins | 2 | 2012 | 33 | 0.190 |
Why?
| | Liver Diseases | 2 | 2007 | 282 | 0.190 |
Why?
| | Surgical Stomas | 1 | 2000 | 6 | 0.190 |
Why?
| | Colostomy | 1 | 2000 | 26 | 0.190 |
Why?
| | Sensitivity and Specificity | 9 | 2012 | 1795 | 0.190 |
Why?
| | Thrombolytic Therapy | 2 | 1998 | 117 | 0.190 |
Why?
| | Varicose Veins | 1 | 2000 | 15 | 0.190 |
Why?
| | Infusions, Intra-Arterial | 9 | 2010 | 46 | 0.190 |
Why?
| | Lumbosacral Region | 1 | 2020 | 50 | 0.180 |
Why?
| | Hepatorenal Syndrome | 1 | 2019 | 14 | 0.180 |
Why?
| | Budd-Chiari Syndrome | 1 | 1999 | 9 | 0.180 |
Why?
| | Laminoplasty | 1 | 2019 | 1 | 0.180 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2000 | 109 | 0.180 |
Why?
| | Image Interpretation, Computer-Assisted | 3 | 2011 | 220 | 0.170 |
Why?
| | Laminectomy | 1 | 2019 | 26 | 0.170 |
Why?
| | Iliac Artery | 2 | 2018 | 44 | 0.170 |
Why?
| | Follow-Up Studies | 10 | 2013 | 4596 | 0.170 |
Why?
| | Specialization | 1 | 2020 | 120 | 0.170 |
Why?
| | Prospective Studies | 13 | 2014 | 6477 | 0.170 |
Why?
| | Ohio | 1 | 2019 | 141 | 0.170 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2010 | 90 | 0.170 |
Why?
| | Bile Ducts | 1 | 2019 | 73 | 0.170 |
Why?
| | Glass | 3 | 2013 | 44 | 0.170 |
Why?
| | Models, Educational | 1 | 2019 | 99 | 0.160 |
Why?
| | Survival Analysis | 6 | 2011 | 1267 | 0.160 |
Why?
| | Mesenteric Veins | 1 | 1998 | 10 | 0.160 |
Why?
| | Young Adult | 7 | 2018 | 10799 | 0.160 |
Why?
| | Biliary Fistula | 1 | 1998 | 3 | 0.160 |
Why?
| | Intestine, Small | 1 | 2019 | 131 | 0.160 |
Why?
| | Patient Selection | 5 | 2015 | 675 | 0.160 |
Why?
| | Urinary Fistula | 1 | 1998 | 9 | 0.160 |
Why?
| | Catheters | 2 | 2015 | 61 | 0.160 |
Why?
| | Thrombectomy | 1 | 1998 | 59 | 0.160 |
Why?
| | Writing | 1 | 2019 | 88 | 0.160 |
Why?
| | Liver Circulation | 4 | 2015 | 23 | 0.150 |
Why?
| | Pain | 1 | 2003 | 736 | 0.150 |
Why?
| | Patient Advocacy | 1 | 2017 | 66 | 0.150 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2019 | 202 | 0.150 |
Why?
| | Treatment Failure | 4 | 2017 | 341 | 0.150 |
Why?
| | Radiography | 7 | 2012 | 861 | 0.150 |
Why?
| | Ultrasonography, Doppler, Color | 2 | 2008 | 35 | 0.140 |
Why?
| | Hemostasis, Surgical | 1 | 2016 | 22 | 0.140 |
Why?
| | Vena Cava, Superior | 1 | 2016 | 21 | 0.140 |
Why?
| | Drug Utilization | 1 | 2017 | 169 | 0.140 |
Why?
| | United States Food and Drug Administration | 1 | 2017 | 175 | 0.140 |
Why?
| | Cell Line, Tumor | 7 | 2013 | 2851 | 0.140 |
Why?
| | Lower Extremity | 1 | 2020 | 335 | 0.140 |
Why?
| | History, 20th Century | 1 | 2017 | 281 | 0.140 |
Why?
| | Doxorubicin | 3 | 2013 | 302 | 0.140 |
Why?
| | Portal Pressure | 1 | 2016 | 6 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2019 | 422 | 0.140 |
Why?
| | Balloon Occlusion | 1 | 2016 | 26 | 0.140 |
Why?
| | Research Design | 3 | 2013 | 969 | 0.140 |
Why?
| | Gadolinium DTPA | 5 | 2014 | 54 | 0.140 |
Why?
| | Anatomic Landmarks | 1 | 2016 | 28 | 0.140 |
Why?
| | Finite Element Analysis | 1 | 2016 | 70 | 0.140 |
Why?
| | Reproducibility of Results | 8 | 2011 | 2874 | 0.140 |
Why?
| | Operative Time | 1 | 2016 | 114 | 0.130 |
Why?
| | Aorta | 1 | 2018 | 367 | 0.130 |
Why?
| | Adolescent | 14 | 2018 | 18483 | 0.130 |
Why?
| | Radiation Exposure | 1 | 2016 | 44 | 0.130 |
Why?
| | Stomach | 2 | 2013 | 103 | 0.130 |
Why?
| | Models, Anatomic | 1 | 2016 | 94 | 0.130 |
Why?
| | Sex Factors | 2 | 2018 | 1781 | 0.130 |
Why?
| | Bile Ducts, Intrahepatic | 3 | 2013 | 53 | 0.130 |
Why?
| | Hospital Mortality | 2 | 2018 | 814 | 0.130 |
Why?
| | Intraoperative Complications | 1 | 2016 | 132 | 0.130 |
Why?
| | Wounds, Nonpenetrating | 4 | 2000 | 285 | 0.130 |
Why?
| | Cisplatin | 3 | 2012 | 271 | 0.130 |
Why?
| | Length of Stay | 2 | 2019 | 1031 | 0.130 |
Why?
| | Dilatation | 1 | 2015 | 56 | 0.130 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 399 | 0.130 |
Why?
| | Wounds, Gunshot | 1 | 1998 | 176 | 0.130 |
Why?
| | Carotid Artery Injuries | 3 | 2000 | 42 | 0.120 |
Why?
| | Data Interpretation, Statistical | 3 | 2013 | 336 | 0.120 |
Why?
| | Biopsy | 3 | 2014 | 1079 | 0.120 |
Why?
| | End Stage Liver Disease | 1 | 2015 | 73 | 0.120 |
Why?
| | Foreign-Body Migration | 1 | 2014 | 37 | 0.120 |
Why?
| | Carbon Dioxide | 1 | 2016 | 230 | 0.120 |
Why?
| | Stress, Mechanical | 1 | 2016 | 443 | 0.120 |
Why?
| | Peripheral Arterial Disease | 1 | 2020 | 378 | 0.120 |
Why?
| | Anticoagulants | 2 | 2017 | 559 | 0.120 |
Why?
| | Magnetite Nanoparticles | 1 | 2013 | 28 | 0.120 |
Why?
| | Duodenum | 1 | 2013 | 67 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 1390 | 0.120 |
Why?
| | Kidney Diseases | 1 | 1998 | 442 | 0.110 |
Why?
| | Arthroscopy | 3 | 1992 | 234 | 0.110 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 683 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2017 | 699 | 0.110 |
Why?
| | Catheterization, Peripheral | 3 | 2008 | 107 | 0.110 |
Why?
| | Proportional Hazards Models | 5 | 2014 | 1125 | 0.110 |
Why?
| | Acromion | 1 | 1992 | 8 | 0.110 |
Why?
| | Fibrin | 1 | 2012 | 60 | 0.110 |
Why?
| | Shoulder Injuries | 1 | 1992 | 62 | 0.110 |
Why?
| | Electroporation | 1 | 2012 | 33 | 0.100 |
Why?
| | Fibromuscular Dysplasia | 1 | 2011 | 4 | 0.100 |
Why?
| | Respiratory-Gated Imaging Techniques | 1 | 2011 | 8 | 0.100 |
Why?
| | Rotator Cuff | 1 | 1992 | 52 | 0.100 |
Why?
| | Tendon Injuries | 1 | 1992 | 80 | 0.100 |
Why?
| | Prognosis | 5 | 2010 | 3443 | 0.100 |
Why?
| | Comorbidity | 1 | 2016 | 1527 | 0.100 |
Why?
| | Neuroendocrine Tumors | 1 | 2011 | 83 | 0.100 |
Why?
| | Yttrium | 1 | 2010 | 5 | 0.100 |
Why?
| | Biomarkers, Tumor | 3 | 2012 | 1059 | 0.090 |
Why?
| | Research Report | 1 | 2011 | 75 | 0.090 |
Why?
| | Injections, Intra-Arterial | 5 | 2012 | 25 | 0.090 |
Why?
| | Surgery, Computer-Assisted | 1 | 2011 | 69 | 0.090 |
Why?
| | Decision Support Techniques | 1 | 2014 | 364 | 0.090 |
Why?
| | Punctures | 1 | 2010 | 39 | 0.090 |
Why?
| | Gastrostomy | 2 | 2009 | 93 | 0.090 |
Why?
| | Biopsy, Fine-Needle | 1 | 2009 | 69 | 0.090 |
Why?
| | Breast Neoplasms | 2 | 2014 | 1965 | 0.090 |
Why?
| | Palliative Care | 1 | 2015 | 629 | 0.090 |
Why?
| | Pancreatic Pseudocyst | 1 | 2009 | 13 | 0.090 |
Why?
| | Bilirubin | 3 | 2010 | 95 | 0.080 |
Why?
| | Practice Guidelines as Topic | 4 | 2013 | 1440 | 0.080 |
Why?
| | Prevalence | 2 | 2012 | 2326 | 0.080 |
Why?
| | Necrosis | 4 | 2010 | 231 | 0.080 |
Why?
| | Cohort Studies | 4 | 2018 | 5117 | 0.080 |
Why?
| | Radiation Pneumonitis | 1 | 2008 | 26 | 0.080 |
Why?
| | Ambulatory Care Facilities | 1 | 2010 | 219 | 0.080 |
Why?
| | Liver Function Tests | 3 | 2015 | 107 | 0.080 |
Why?
| | Biliary Tract | 1 | 2008 | 17 | 0.080 |
Why?
| | Radiotherapy Dosage | 4 | 2010 | 245 | 0.080 |
Why?
| | Animals | 13 | 2016 | 33399 | 0.080 |
Why?
| | Maximum Allowable Concentration | 1 | 2007 | 14 | 0.080 |
Why?
| | Knee Injuries | 1 | 1989 | 103 | 0.080 |
Why?
| | Subtraction Technique | 1 | 2007 | 27 | 0.080 |
Why?
| | Neoplasm Transplantation | 1 | 2008 | 245 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2009 | 1384 | 0.080 |
Why?
| | Endpoint Determination | 3 | 2013 | 69 | 0.080 |
Why?
| | Incidence | 3 | 2009 | 2424 | 0.080 |
Why?
| | Vacuum Curettage | 1 | 2007 | 5 | 0.080 |
Why?
| | Diagnostic Errors | 1 | 2008 | 162 | 0.080 |
Why?
| | Catheterization, Central Venous | 2 | 1999 | 95 | 0.070 |
Why?
| | Leiomyomatosis | 1 | 2006 | 1 | 0.070 |
Why?
| | Credentialing | 1 | 2006 | 12 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 246 | 0.070 |
Why?
| | Image Enhancement | 4 | 2011 | 181 | 0.070 |
Why?
| | Iron | 1 | 2008 | 248 | 0.070 |
Why?
| | Radiotherapy | 1 | 2008 | 187 | 0.070 |
Why?
| | Ultrasonography | 2 | 2015 | 716 | 0.070 |
Why?
| | Knee Joint | 1 | 1989 | 353 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2008 | 325 | 0.070 |
Why?
| | Personnel Selection | 1 | 2006 | 71 | 0.070 |
Why?
| | Ethics, Research | 1 | 2005 | 31 | 0.070 |
Why?
| | Fluorescent Dyes | 1 | 2007 | 316 | 0.070 |
Why?
| | Decision Making | 1 | 2012 | 809 | 0.070 |
Why?
| | Regional Blood Flow | 2 | 2007 | 418 | 0.070 |
Why?
| | Heart Failure | 1 | 2018 | 1968 | 0.070 |
Why?
| | Organ Size | 3 | 2013 | 460 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2011 | 585 | 0.060 |
Why?
| | Postmenopause | 1 | 2007 | 306 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1167 | 0.060 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2004 | 39 | 0.060 |
Why?
| | Pilot Projects | 4 | 2009 | 1420 | 0.060 |
Why?
| | Odds Ratio | 2 | 2017 | 996 | 0.060 |
Why?
| | Dose-Response Relationship, Radiation | 3 | 2008 | 129 | 0.060 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2003 | 10 | 0.060 |
Why?
| | Fellowships and Scholarships | 1 | 2006 | 250 | 0.060 |
Why?
| | Ischemia | 1 | 2006 | 374 | 0.060 |
Why?
| | Illinois | 3 | 2009 | 38 | 0.060 |
Why?
| | Menisci, Tibial | 2 | 1995 | 59 | 0.050 |
Why?
| | Hepatectomy | 2 | 2013 | 139 | 0.050 |
Why?
| | Feasibility Studies | 3 | 2011 | 749 | 0.050 |
Why?
| | Aneurysm, False | 2 | 2000 | 46 | 0.050 |
Why?
| | Colorectal Neoplasms | 1 | 2009 | 628 | 0.050 |
Why?
| | Drug Stability | 2 | 2013 | 153 | 0.050 |
Why?
| | Tumor Burden | 2 | 2014 | 275 | 0.050 |
Why?
| | Confidence Intervals | 2 | 2013 | 324 | 0.050 |
Why?
| | World Health Organization | 2 | 2012 | 107 | 0.050 |
Why?
| | Recurrence | 2 | 2000 | 975 | 0.050 |
Why?
| | Europe | 2 | 2012 | 356 | 0.050 |
Why?
| | Administrative Claims, Healthcare | 1 | 2020 | 22 | 0.050 |
Why?
| | Carotid Artery, Internal | 1 | 2000 | 34 | 0.050 |
Why?
| | Radiologists | 1 | 2020 | 38 | 0.040 |
Why?
| | Cardiologists | 1 | 2020 | 40 | 0.040 |
Why?
| | Disease-Free Survival | 2 | 2013 | 649 | 0.040 |
Why?
| | Hospitalization | 2 | 2020 | 1785 | 0.040 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2020 | 50 | 0.040 |
Why?
| | Menstrual Cycle | 1 | 2000 | 113 | 0.040 |
Why?
| | Hepatic Encephalopathy | 1 | 1999 | 22 | 0.040 |
Why?
| | Evidence-Based Medicine | 2 | 2013 | 693 | 0.040 |
Why?
| | Tomography, Emission-Computed | 2 | 2009 | 58 | 0.040 |
Why?
| | Tracheoesophageal Fistula | 1 | 1999 | 33 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2019 | 146 | 0.040 |
Why?
| | Liver Failure | 1 | 1999 | 85 | 0.040 |
Why?
| | Streptokinase | 1 | 1998 | 11 | 0.040 |
Why?
| | Postoperative Hemorrhage | 1 | 1999 | 79 | 0.040 |
Why?
| | Serum Albumin | 1 | 1999 | 147 | 0.040 |
Why?
| | Multiple Organ Failure | 1 | 1999 | 150 | 0.040 |
Why?
| | Ethiodized Oil | 2 | 2008 | 5 | 0.040 |
Why?
| | Equipment Design | 2 | 2012 | 519 | 0.040 |
Why?
| | Mitomycin | 2 | 2008 | 27 | 0.040 |
Why?
| | Swine | 2 | 2016 | 731 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2011 | 1295 | 0.040 |
Why?
| | Guidelines as Topic | 2 | 2010 | 262 | 0.040 |
Why?
| | Nervous System Diseases | 2 | 2017 | 261 | 0.040 |
Why?
| | Cause of Death | 1 | 1999 | 380 | 0.040 |
Why?
| | Cartilage Diseases | 2 | 1995 | 47 | 0.040 |
Why?
| | Intracranial Hypertension | 1 | 1997 | 41 | 0.040 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1997 | 113 | 0.040 |
Why?
| | Radiography, Thoracic | 1 | 1997 | 164 | 0.040 |
Why?
| | Tuberculosis, Pulmonary | 1 | 1997 | 112 | 0.040 |
Why?
| | Abdominal Injuries | 1 | 1998 | 119 | 0.040 |
Why?
| | Demography | 1 | 2017 | 274 | 0.040 |
Why?
| | Acute Disease | 1 | 1999 | 941 | 0.040 |
Why?
| | Recovery of Function | 1 | 2000 | 604 | 0.030 |
Why?
| | Positron-Emission Tomography | 2 | 2008 | 298 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2020 | 482 | 0.030 |
Why?
| | Databases as Topic | 2 | 2010 | 73 | 0.030 |
Why?
| | Surgeons | 1 | 2020 | 243 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2003 | 3173 | 0.030 |
Why?
| | Inpatients | 1 | 2019 | 389 | 0.030 |
Why?
| | Lung | 1 | 2008 | 3666 | 0.030 |
Why?
| | Fibrinolytic Agents | 1 | 1998 | 237 | 0.030 |
Why?
| | Models, Cardiovascular | 1 | 2016 | 180 | 0.030 |
Why?
| | Phantoms, Imaging | 2 | 2008 | 139 | 0.030 |
Why?
| | Cysts | 1 | 1995 | 93 | 0.030 |
Why?
| | Embolism | 2 | 2008 | 43 | 0.030 |
Why?
| | Preoperative Care | 1 | 2016 | 332 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 505 | 0.030 |
Why?
| | Vascular Surgical Procedures | 1 | 2016 | 262 | 0.030 |
Why?
| | Ablation Techniques | 1 | 2013 | 29 | 0.030 |
Why?
| | Eligibility Determination | 1 | 2013 | 55 | 0.030 |
Why?
| | Scapula | 1 | 1992 | 44 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2013 | 189 | 0.030 |
Why?
| | Biomarkers | 2 | 2014 | 3590 | 0.030 |
Why?
| | Nausea | 1 | 2011 | 107 | 0.030 |
Why?
| | Muscular Diseases | 1 | 1992 | 107 | 0.020 |
Why?
| | Vomiting | 1 | 2011 | 123 | 0.020 |
Why?
| | International Agencies | 1 | 2010 | 29 | 0.020 |
Why?
| | Neoadjuvant Therapy | 1 | 2013 | 333 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2010 | 57 | 0.020 |
Why?
| | Abdominal Pain | 1 | 2011 | 134 | 0.020 |
Why?
| | Diarrhea | 1 | 2011 | 181 | 0.020 |
Why?
| | Risk Assessment | 2 | 2009 | 3057 | 0.020 |
Why?
| | Registries | 1 | 2018 | 1810 | 0.020 |
Why?
| | Standard of Care | 1 | 2010 | 63 | 0.020 |
Why?
| | Yttrium Isotopes | 1 | 2009 | 1 | 0.020 |
Why?
| | Fatigue | 1 | 2011 | 297 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2010 | 305 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2010 | 158 | 0.020 |
Why?
| | Terminology as Topic | 1 | 2011 | 211 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 2995 | 0.020 |
Why?
| | Range of Motion, Articular | 1 | 1992 | 369 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1637 | 0.020 |
Why?
| | Fibula | 1 | 1989 | 41 | 0.020 |
Why?
| | ROC Curve | 1 | 2010 | 473 | 0.020 |
Why?
| | Ligaments, Articular | 1 | 1989 | 52 | 0.020 |
Why?
| | Rhenium | 1 | 2008 | 9 | 0.020 |
Why?
| | Radioisotopes | 1 | 2008 | 34 | 0.020 |
Why?
| | Iohexol | 1 | 2008 | 21 | 0.020 |
Why?
| | Body Burden | 1 | 2007 | 5 | 0.020 |
Why?
| | Hysterosalpingography | 1 | 2007 | 6 | 0.020 |
Why?
| | Femur | 1 | 1989 | 199 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2478 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2008 | 334 | 0.020 |
Why?
| | Tibia | 1 | 1989 | 177 | 0.020 |
Why?
| | Celiac Artery | 1 | 2007 | 9 | 0.020 |
Why?
| | Hindlimb | 1 | 2008 | 137 | 0.020 |
Why?
| | Injections | 1 | 2008 | 167 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 984 | 0.020 |
Why?
| | Mesenteric Arteries | 1 | 2007 | 16 | 0.020 |
Why?
| | Equipment Failure Analysis | 1 | 2007 | 139 | 0.020 |
Why?
| | Contraindications | 1 | 2007 | 86 | 0.020 |
Why?
| | Weight Loss | 1 | 2011 | 658 | 0.020 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2007 | 109 | 0.020 |
Why?
| | Injury Severity Score | 2 | 2000 | 528 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2008 | 874 | 0.020 |
Why?
| | Retreatment | 1 | 2005 | 71 | 0.020 |
Why?
| | Cartilage, Articular | 1 | 1989 | 306 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 1244 | 0.020 |
Why?
| | Rats | 1 | 2013 | 5394 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2007 | 544 | 0.020 |
Why?
| | Algorithms | 1 | 2011 | 1543 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 9493 | 0.010 |
Why?
| | Child | 3 | 2017 | 19137 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 2002 | 327 | 0.010 |
Why?
| | Models, Animal | 1 | 2002 | 363 | 0.010 |
Why?
| | Aorta, Abdominal | 1 | 2000 | 40 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 2000 | 88 | 0.010 |
Why?
| | Pneumonia, Aspiration | 1 | 1999 | 16 | 0.010 |
Why?
| | Hematoma | 1 | 1999 | 51 | 0.010 |
Why?
| | Veins | 1 | 1999 | 60 | 0.010 |
Why?
| | Esophageal Stenosis | 1 | 1999 | 47 | 0.010 |
Why?
| | Aortic Diseases | 1 | 2000 | 94 | 0.010 |
Why?
| | Intubation, Gastrointestinal | 1 | 1999 | 61 | 0.010 |
Why?
| | Decision Trees | 1 | 1998 | 83 | 0.010 |
Why?
| | Arm | 1 | 1999 | 106 | 0.010 |
Why?
| | Peripheral Nervous System Diseases | 1 | 1999 | 122 | 0.010 |
Why?
| | Cerebral Infarction | 1 | 1997 | 45 | 0.010 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1997 | 64 | 0.010 |
Why?
| | Los Angeles | 1 | 1997 | 60 | 0.010 |
Why?
| | Carotid Artery Diseases | 1 | 1997 | 58 | 0.010 |
Why?
| | Neurologic Examination | 1 | 1997 | 126 | 0.010 |
Why?
| | Enteral Nutrition | 1 | 1999 | 172 | 0.010 |
Why?
| | Clinical Protocols | 1 | 1998 | 238 | 0.010 |
Why?
| | Intracranial Pressure | 1 | 1997 | 53 | 0.010 |
Why?
| | Glasgow Coma Scale | 1 | 1997 | 150 | 0.010 |
Why?
| | Carotid Stenosis | 1 | 1997 | 75 | 0.010 |
Why?
| | Multiple Trauma | 1 | 1997 | 97 | 0.010 |
Why?
| | Angioplasty, Balloon | 1 | 1997 | 88 | 0.010 |
Why?
| | Heparin | 1 | 1997 | 230 | 0.010 |
Why?
| | Carotid Arteries | 1 | 1997 | 184 | 0.010 |
Why?
| | HIV | 1 | 1997 | 210 | 0.010 |
Why?
| | DNA, Bacterial | 1 | 1997 | 314 | 0.010 |
Why?
| | Craniocerebral Trauma | 1 | 1997 | 146 | 0.010 |
Why?
| | Cluster Analysis | 1 | 1997 | 481 | 0.010 |
Why?
| | Synovial Cyst | 1 | 1995 | 2 | 0.010 |
Why?
| | DNA, Viral | 1 | 1997 | 356 | 0.010 |
Why?
| | Mycobacterium tuberculosis | 1 | 1997 | 266 | 0.010 |
Why?
| | Brain Ischemia | 1 | 1997 | 309 | 0.010 |
Why?
| | Brain Injuries | 1 | 1997 | 484 | 0.010 |
Why?
| | Tibial Meniscus Injuries | 1 | 1990 | 46 | 0.010 |
Why?
| | Postoperative Period | 1 | 1990 | 309 | 0.010 |
Why?
|
|
Ryu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|